Taro Pharmaceuticals recalls seizure drug

Taro Pharmaceuticals is recalling two lots of its Phenytoin seizure drug due to an issue with the packaging that may cause under or overdosing, the drugmaker said Feb. 21. 

The drugmaker said product from the affected lots may not re-suspend when shaken as it is supposed to do, which could cause under or overdosing. 

Infants and children using the drug are at the most risk, as Taro said there is a reasonable probability that inaccurate dosing could cause serious adverse effects such as intoxication or breakthrough seizures requiring medical intervention.

"For a small minority of patients, who might have severe or repeated breakthrough seizures, a drop in their phenytoin blood levels could result in life-threatening status epilepticus requiring immediate emergency room treatment," Taro said. 

Taro said it hasn't received any adverse event reports related to the recall.

Read the full news release here

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars